Nikola Ivica
Co-founder & Chief Scientific Officer InnDura Therapeutics
Nikola A. Ivica, PhD is a co-founder and Chief Scientific Officer of InnDura Therapeutics, where he is advancing innovative cell and gene therapy platforms for a range of therapeutic indications. He trained at MIT as a PhD student and postdoctoral fellow with Professor Jianzhu Chen, PhD and completed his undergraduate studies at Harvard University.
Seminars
Tuesday 21st July 2026
A Hierarchical Two-Tier Gene Delivery Architecture for High-Precision In Vivo Reprogramming of Immune Cells
12:00 pm
- EVE16 is a next-generation immuno-activating receptor with cell-type–restricted expression in T cells, NK cells, and monocytes and active degradation in off-target tissues
- EVE16 mediates strong antigen-dependent cytotoxic responses while avoiding tonic signaling and trogocytosis
- EVE16 functionally cooperates with therapeutic monoclonal antibodies to amplify ADCC against diverse antigen-expressing cells
